In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
BO-2727, a new 1-beta-methyl-carbapenem, was active at concentrations of 6.25 micrograms/ml or less against gram-positive and gram-negative bacteria, including some imipenem- and/or meropenem-resistant (MICs, > or = 12.5 micrograms/ml) Pseudomonas aeruginosa strains, against which it proved generally fourfold more active than imipenem and meropenem. BO-2727's antipseudomonal activity and its broad spectrum merit further investigation for clinical use by itself, since it was stable in the presence of renal dehydropeptidase I.
Nakagawa
S
S
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Japan.
Hashizume
T
T
Matsuda
K
K
Sanada
M
M
Okamoto
O
O
Fukatsu
H
H
Tanaka
N
N
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D015780:Carbapenems / Q000378:metabolism / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D004150:Dipeptidases / Q000378:metabolism; D004355:Drug Stability; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006868:Hydrolysis; D015378:Imipenem / Q000494:pharmacology; D007668:Kidney / Q000201:enzymology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D011549:Pseudomonas / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; C085890:BO 2727; D015378:Imipenem; D002442:Ceftazidime; D004150:Dipeptidases; C038937:dipeptidase; D000077731:Meropenem